Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK), AbbVie (ABBV) and Intercept Pharma (ICPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRKResearch Report), AbbVie (ABBVResearch Report) and Intercept Pharma (ICPTResearch Report).

Merck & Company (MRK)

In a report released today, Daina Graybosch from SVB Securities maintained a Buy rating on Merck & Company, with a price target of $110.00. The company’s shares closed last Friday at $86.19.

According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of -19.9% and a 27.6% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, Century Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $100.73.

See the top stocks recommended by analysts >>

AbbVie (ABBV)

SVB Securities analyst David Risinger maintained a Sell rating on AbbVie today and set a price target of $135.00. The company’s shares closed last Friday at $134.37.

According to TipRanks.com, Risinger is a 3-star analyst with an average return of 6.3% and a 45.5% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Prometheus Biosciences, and Theravance Biopharma.

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $160.50.

Intercept Pharma (ICPT)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Intercept Pharma today and set a price target of $28.00. The company’s shares closed last Friday at $14.01.

According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of -28.8% and a 21.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $27.67, implying an 85.7% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $49.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos